ISIS 416858

Synonyms: FXI-ASO; BAY2306001; IONIS-FXIRx
ISIS 416858(FXI-ASO;BAY2306001;IONIS-FXIRx)是一种靶向凝血因子XI(FXI)的反义寡核苷酸,具有卓越的抗栓疗效且不增加出血风险,可用于术后静脉血栓栓塞及血栓性疾病的相关研究。
产品编号: MS-J36266 纯度: 96.10% CAS No.: 1223657-78-0
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

ISIS 416858(FXI-ASO;BAY2306001;IONIS-FXIRx)是一种靶向凝血因子XI(FXI)的反义寡核苷酸,具有卓越的抗栓疗效且不增加出血风险,可用于术后静脉血栓栓塞及血栓性疾病的相关研究。

生物实验数据

生物活性 ISIS 416858 (FXI-ASO; BAY2306001; IONIS-FXIRx) is an antisense oligonucleotide targeting coagulation factor XI (FXI) that exhibits superior antithrombotic efficacy without increasing bleeding risk and can be used for research on postoperative venous thromboembolism and thrombotic diseases.
体内研究
(In Vivo)

ISIS 416858 (2.5-10 mg/kg;皮下注射;每周 1 次;共 4 剂) 可剂量依赖性地降低食蟹猴体内的因子 XI 活性,在不损伤止血功能的剂量下抑制三氯化铁诱导的腔静脉血栓形成。
ISIS 416858 (1-10 mg/kg;皮下注射;每周 1 次;共 3 剂) 可剂量依赖性地降低食蟹猴 体内的因子 XI 活性并延长 aPTT,且在可显著降低因子 XI 水平的剂量下不会损伤止血功能。
ISIS 416858 (25-50 mg/kg;皮下注射;每 3 天 1 次;共 3 剂),可呈剂量依赖性降低凝血因子 XI 活性,并在小鼠中抑制氯化铁诱导的腔静脉血栓形成,且不会增加出血风险。
ISIS 416858 (4-40 mg/kg;静脉输注、皮下注射;隔日给药 (2 周诱导期),每周 1 次 (维持期,最长 13 周)) 可剂量和时间依赖性地抑制食蟹猴肝脏 FXI mRNA 的表达及血浆 FXI 的活性,同时伴随 APTT 相应升高,且停药后上述作用基本可逆。

Animal Model: Macaca fascicularis
Dosage: 2.5 mg/kg; 5 mg/kg; 10 mg/kg
Administration: s.c.; weekly; 4 doses
Result: Reduced factor XI activity to ~10% of baseline (10 mg/kg).
Inhibited vena cava thrombus formation by > 90% compared to controls (10 mg/kg).
Caused no significant increase in bleeding time or blood loss in a liver laceration hemostasis model (10 mg/kg).
Reduced factor XI activity to ~30% of baseline and inhibited thrombus formation with no increase in bleeding (5 mg/kg).
Reduced factor XI activity to ~50% of baseline (2.5 mg/kg).
Animal Model: Macaca fascicularis
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: s.c.; weekly; 3 doses
Result: Reduced factor XI activity to ~15% of baseline and prolonged aPTT to ~1.8 times baseline, but did not significantly increase template bleeding time or blood loss from a liver punch biopsy model (10 mg/kg).
Reduced factor XI activity to ~40% of baseline and prolonged aPTT to ~1.3 times baseline, with no effect on hemostatic parameters (3 mg/kg).
Reduced factor XI activity to ~70% of baseline with minimal aPTT prolongation (1 mg/kg).
Animal Model: C57BL/6
Dosage: 25 mg/kg; 50 mg/kg
Administration: s.c.; every 3 days; 3 doses
Result: Reduced mouse factor XI activity to ~10% of baseline and reduced vena cava thrombus weight by ~80% compared to controls (50 mg/kg).
Reduced factor XI activity to ~30% of baseline and reduced thrombus weight by ~50% (25 mg/kg).
Neither dose increased tail bleeding time compared to controls.
Animal Model: Cynomolgus monkeys (male and female, Asian origin, 2.5-3.5 kg, 2-5 years old)
Dosage: 4 mg/kg; 8 mg/kg; 12 mg/kg; 40 mg/kg
Administration: i.v. infusion (first 3 doses for ≤ 12 mg/kg); s.c. injection (subsequent doses for ≤ 12 mg/kg; all doses for 40 mg/kg); every other day (2-week loading phase); once weekly (maintenance, up to 13 weeks)
Result: Reduced liver FXI mRNA by 50% (12 mg/kg, day 44); 90% (40 mg/kg, day 44); 50% (4 mg/kg, day 93); 90% (40 mg/kg, day 93).
Reduced liver FXI mRNA by 44% (40 mg/kg, post 13-week recovery); showed near-complete recovery (12 mg/kg, post 13-week recovery).
Reduced plasma FXI activity by 25% (40 mg/kg, day 8); 75% (40 mg/kg, day 21, maintained through 13 weeks); 15-20% (4 mg/kg, day 28).
Reduced plasma FXI activity by 25% (40 mg/kg, post 13-week recovery); showed complete recovery (12 mg/kg, post 13-week recovery).
Increased APTT by 75% (40 mg/kg, 13 weeks); 20% (12 mg/kg, 13 weeks); 10% (8 mg/kg, 13 weeks).
Restored APTT to control levels (post 13-week recovery).
Achieved ED50 of ~4 mg/kg (liver FXI mRNA inhibition, 13 weeks); ~16 mg/kg (plasma FXI activity reduction, 13 weeks); ~17 mg/kg (APTT elevation, 13 weeks).
性状 固体
颜色 White to off-white

化学信息

CAS No. 1223657-78-0
别名 FXI-ASO; BAY2306001; IONIS-FXIRx

储存&溶解度

储存方式

-20°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础